← ANALYST RATINGS · TIPRANKS
Tectonic Therapeutic (TECX): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy1 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $69.75, the highest $93.00, the lowest $26.00. The average is +237.8% from the last price of $20.65.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $21.50 → $21.00−2.3% | Hold | +1.7% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $20.50 → $20.00−2.4% | Hold | −3.1% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $20.50 → $20.00−2.4% | Hold | −3.1% | Upgrade | 17.10.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $21.00 → $20.50−2.4% | Hold | −0.7% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | $60.00 | Buy | +190.6% | Reiterated | 15.10.26on TipRanks Oct 16 06:50 | +1.3%next day −1.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $23.50 → $21.50−8.5% | Hold | +4.1% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $23.00 → $20.50−10.9% | Hold | −0.7% | Upgrade | 15.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $23.00 → $20.50−10.9% | Hold | −0.7% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $23.00 → $20.50−10.9% | Hold | −0.7% | Upgrade | 15.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $23.50 → $21.00−10.6% | Hold | +1.7% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $23.00 → $20.50−10.9% | Hold | −0.7% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $76.00 | Buy | +268.0% | Reiterated | 14.10.26on TipRanks 07:25 | −0.6%next day +1.3% | ↗ |
| Name not given | — | $26.00 | Hold | +25.9% | Initiated | 11.10.26on TipRanks Oct 12 05:55 | −4.1%next day −4.6% | ↗ |
| James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% | Stifel Nicolaus | $75.00 | Buy | +263.2% | Reiterated | 01.10.26on TipRanks 10:15 | −2.8%next day −1.3% · 5 days −0.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $24.50 → $23.50−4.1% | Hold | +13.8% | Reiterated | 30.09.26on TipRanks 08:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $23.50 → $23.00−2.1% | Hold | +11.4% | Upgrade | 30.09.26on TipRanks 08:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $24.00 → $23.00−4.2% | Hold | +11.4% | Reiterated | 30.09.26on TipRanks 08:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $23.50 → $23.00−2.1% | Hold | +11.4% | Upgrade | 30.09.26on TipRanks 08:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $24.00 → $23.50−2.1% | Hold | +13.8% | Reiterated | 30.09.26on TipRanks 08:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $24.00 → $23.00−4.2% | Hold | +11.4% | Reiterated | 30.09.26on TipRanks 08:05 | — | |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $76.00 | Buy | +268.0% | Reiterated | 30.09.26on TipRanks 07:55 | 0.0%next day −2.8% · 5 days −4.4% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $93.00 | Buy | +350.4% | Assigned | 29.09.26on TipRanks Sep 30 04:50 | −0.5%next day 0.0% · 5 days −5.9% | ↗ |
| Gaurav Maini★★★★★★★★★★#2199 · hits 88% · avg +29.5% | LifeSci Capital | $88.00 | Buy | +326.2% | Reiterated | 29.09.26on TipRanks 11:09 | −0.5%next day 0.0% · 5 days −5.9% | ↗ |
| Unknown Analyst | Oppenheimer | $80.00 | Buy | +287.4% | Reiterated | 01.09.26on TipRanks Sep 7 01:05 | +5.0%next day −3.1% · 5 days −2.5% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | $60.00 | Buy | +190.6% | Reiterated | 10.08.26on TipRanks 07:55 | +5.6%next day −2.2% · 5 days +3.5% | ↗ |
| James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% | Stifel Nicolaus | $75.00 | Buy | +263.2% | Reiterated | 07.08.26on TipRanks 08:15 | +1.9%next day +5.6% · 5 days +12.3% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $76.00 → $81.00+6.6% | Buy | +292.3% | Reiterated | 26.05.26on TipRanks 05:25 | +2.3%next day +1.5% · 5 days −9.7% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Reiterated | 08.05.26on TipRanks 00:36 | +7.1%next day −5.3% · 5 days −4.0% | ↗ |
| Unknown Analyst | Roth MKM | $80.00 | Buy | +287.4% | Reiterated | 30.10.25on TipRanks 08:20 | −4.4%next day +3.4% · 5 days +9.3% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Tectonic Therapeutic
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $78.67 at a price of $23.29 (+237.8%); now: $69.75 at $20.65 (+237.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 16 | 15 | 11 | 12 | 15 |
| Buy | 3 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.32 (from $-1.54 to $-1.09). Last quarter: $-1.18.
Best top-analyst consensus in the sector · Healthcare
About Tectonic Therapeutic
- CEO: Alise S. Reicin
- Employees: 60
- 490 Arsenal Way, Watertown, MA, 02472, US
- tectonictx.com
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Data from the stock’s TipRanks forecast page, read 15 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗